Cargando…

Adverse Effects of COX-2 Inhibitors

Cyclooxygenase-2 selective inhibitors (COXIBs) were developed with the prime object of minimizing gastrointestinal adverse effects, which are seen with the use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Their long-term use is limited by the development of hypertension, edema, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Jagdish N., Jawad, Najeeba M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936602/
https://www.ncbi.nlm.nih.gov/pubmed/16113940
http://dx.doi.org/10.1100/tsw.2005.82
_version_ 1783320495394914304
author Sharma, Jagdish N.
Jawad, Najeeba M.
author_facet Sharma, Jagdish N.
Jawad, Najeeba M.
author_sort Sharma, Jagdish N.
collection PubMed
description Cyclooxygenase-2 selective inhibitors (COXIBs) were developed with the prime object of minimizing gastrointestinal adverse effects, which are seen with the use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Their long-term use is limited by the development of hypertension, edema, and congestive heart failure in a significant proportion of patients. NSAIDs block the activity of both COX isozymes, COX-1 and COX-2, which mediate the enzymatic conversion of arachidonate to prostaglandin H(2) (PGH(2)) and other prostaglandin (PG) metabolites. It is well established that the cardiovascular profile of COX-2 inhibitors can be accounted for by inhibition of COX-dependent PG synthesis. Following the COX-mediated synthesis of PGH(2) from arachidonate, PGH(2) is metabolized to one of at least five bioactive PGs, including PGE(2), PGI(2), PGF(2), PGD(2), or thromboxane A(2) (TXA(2)). These prostanoids have pleiotropic cardiovascular effects, altering platelet function and renal function, and they are acting either as vasodilators or vasoconstrictors. Although COX-1 and COX-2 exhibit similar biochemical activity in converting arachidonate to PGH(2)in vitro, the ultimate prostanoids they produce in vivo may be different due to differential regulation of COX-1 and COX-2, tissue distribution, and availability of the prostanoid synthases. PGs have been established as being critically involved in mitigating hypertension, helping to maintain medullary blood flow (MBF), promoting urinary salt excretion, and preserving the normal homeostasis of thrombosis, and the researchers found that the use of COX-2 inhibitors caused many serious complications in altering the normal body homeostasis. The purpose of the present research is to explain briefly the side effects of COX-2 inhibitors on the renal and cardiovascular system.
format Online
Article
Text
id pubmed-5936602
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher TheScientificWorldJOURNAL
record_format MEDLINE/PubMed
spelling pubmed-59366022018-06-03 Adverse Effects of COX-2 Inhibitors Sharma, Jagdish N. Jawad, Najeeba M. ScientificWorldJournal Review Article Cyclooxygenase-2 selective inhibitors (COXIBs) were developed with the prime object of minimizing gastrointestinal adverse effects, which are seen with the use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Their long-term use is limited by the development of hypertension, edema, and congestive heart failure in a significant proportion of patients. NSAIDs block the activity of both COX isozymes, COX-1 and COX-2, which mediate the enzymatic conversion of arachidonate to prostaglandin H(2) (PGH(2)) and other prostaglandin (PG) metabolites. It is well established that the cardiovascular profile of COX-2 inhibitors can be accounted for by inhibition of COX-dependent PG synthesis. Following the COX-mediated synthesis of PGH(2) from arachidonate, PGH(2) is metabolized to one of at least five bioactive PGs, including PGE(2), PGI(2), PGF(2), PGD(2), or thromboxane A(2) (TXA(2)). These prostanoids have pleiotropic cardiovascular effects, altering platelet function and renal function, and they are acting either as vasodilators or vasoconstrictors. Although COX-1 and COX-2 exhibit similar biochemical activity in converting arachidonate to PGH(2)in vitro, the ultimate prostanoids they produce in vivo may be different due to differential regulation of COX-1 and COX-2, tissue distribution, and availability of the prostanoid synthases. PGs have been established as being critically involved in mitigating hypertension, helping to maintain medullary blood flow (MBF), promoting urinary salt excretion, and preserving the normal homeostasis of thrombosis, and the researchers found that the use of COX-2 inhibitors caused many serious complications in altering the normal body homeostasis. The purpose of the present research is to explain briefly the side effects of COX-2 inhibitors on the renal and cardiovascular system. TheScientificWorldJOURNAL 2005-08-18 /pmc/articles/PMC5936602/ /pubmed/16113940 http://dx.doi.org/10.1100/tsw.2005.82 Text en Copyright © 2005 Jagdish N. Sharma and Najeeba M. Jawad. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sharma, Jagdish N.
Jawad, Najeeba M.
Adverse Effects of COX-2 Inhibitors
title Adverse Effects of COX-2 Inhibitors
title_full Adverse Effects of COX-2 Inhibitors
title_fullStr Adverse Effects of COX-2 Inhibitors
title_full_unstemmed Adverse Effects of COX-2 Inhibitors
title_short Adverse Effects of COX-2 Inhibitors
title_sort adverse effects of cox-2 inhibitors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936602/
https://www.ncbi.nlm.nih.gov/pubmed/16113940
http://dx.doi.org/10.1100/tsw.2005.82
work_keys_str_mv AT sharmajagdishn adverseeffectsofcox2inhibitors
AT jawadnajeebam adverseeffectsofcox2inhibitors